BEIJING and SHANGHAI and BOSTON, July 20, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress. The presentation details are as follows:
"We are extremely excited to have the opportunity for an oral presentation at 2023 ESMO Congress, and we hope our data will shed light on clinical development of SHP2 inhibitorsSHP2 inhibitors in solid tumors. On behalf of Jacobio, we extend our sincere appreciation to the patients and investigators who participated this crucial study, and we are committed to advancing the global development of SHP2-based treatment regiments in cancer patients." Said Andrea Wang-Gillam, M.D., Ph.D., Chief Medical Officer of Jacobio.
ESMO Congress 2023 will be held in Madrid, Spain, from October 20 to October 24. For more information, please visit the official website of the ESMO: https://www.esmo.org/
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.